Add to a list

Inactive Instrument

Orgenesis Inc Stock Other OTC

US68619K1051

Medical Equipment, Supplies & Distribution

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâ€™s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâ€™s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	983K 857K 794K 743K 1.39M 92.74M 1.4M 9.42M 3.65M 45.65M 3.69M 3.61M 158M	P/E 2023	-0.26x	P/E 2024	-0.17x
Enterprise Value	19.16M 16.71M 15.48M 14.49M 27.17M 1.81B 27.33M 184M 71.15M 890M 71.94M 70.39M 3.09B	EV / Sales 2023	71.2x	EV / Sales 2024	27x
Free-Float	52.06%	Yield 2023 *	-	Yield 2024	-

03-26	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03-25	Orgenesis Inc. Auditor Raises 'Going Concern' Doubt	CI
03-25	Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc..	CI
03-13	Orgenesis Inc. Announces Board Appointments, Effective March 10, 2026	CI
03-13	Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026	CI
25-08-25	Orgenesis Inc. Announces Resignation of Director Ashish Nanda, Effective August 21, 2025	CI
25-08-19	Orgenesis Inc. Announces Resignation of Victor Miller as Chief Financial Officer	CI
25-08-19	Orgenesis Inc. Announces Executive and Board Changes	CI
25-03-05	Orgenesis Inc. completed the acquisition of Certain assets of Neurocords LLC for $5.7 million.	CI
25-01-21	Orgenesis Inc. announced that it expects to receive $5 million in funding	CI
24-12-27	Orgenesis Inc. Announces Resignation of Jagannathan Bhalaji as A Director	CI
24-11-13	Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	CI
24-11-13	Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

03-26	Orgenesis : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
24-11-13	Orgenesis Provides Third Quarter 2024 Business Update	AQ
24-10-21	Orgenesis Commences Trading on OTCQX® Best Market	AQ
24-09-23	Orgenesis Announces Reverse Stock Split	AQ
24-08-29	Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia	AQ

Manager	Title	Age	Since
Sarah Ferber CTO	Chief Tech/Sci/R&D Officer	72	2012-02-01
Vered Caplan CEO	Chief Executive Officer	57	2013-12-23
Douglas Karriker DFI	Director of Finance/CFO	51	2026-03-09

Director	Title	Age	Since
Vered Caplan CHM	Chairman	57	2014-08-13
Itzhak Vider BRD	Director/Board Member	64	2024-07-07
Adam Pelavin BRD	Director/Board Member	47	2024-10-27

Orgenesis Inc Stock Other OTC

Stocks

US68619K1051

Medical Equipment, Supplies & Distribution

Valuation: Orgenesis Inc

Latest news : Orgenesis Inc

Press Releases: Orgenesis Inc

Quotes and Performance

Managers and Directors: Orgenesis Inc

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORGENESIS INC	+17.76%	+8.82%	-	-	3.12M
ABBOTT LABORATORIES	-0.10%	-1.38%	-33.23%	-16.75%	154B
MEDTRONIC PLC	+1.54%	-1.23%	-7.45%	-11.00%	102B
HOYA CORPORATION	-4.45%	+6.22%	+58.91%	+55.60%	59.25B
CENCORA, INC.	-1.90%	-3.43%	-8.40%	+48.53%	52.89B
BECTON, DICKINSON AND COMPANY	+1.67%	-2.29%	-14.60%	-44.33%	39.67B
MEDLINE INC.	-1.32%	-3.20%	-	-	30.39B
DEXCOM, INC.	+1.74%	-3.69%	-10.54%	-44.30%	27.96B
WEST PHARMACEUTICAL SERVICES, INC.	+1.35%	-0.72%	+50.47%	-9.42%	23.17B
TERUMO CORPORATION	-1.53%	-1.74%	-15.43%	-3.81%	20.7B
Average	+1.48%	-0.50%	+2.47%	-3.18%	56.65B
Weighted average by Cap.	-0.29%	-0.20%	-5.95%	-2.36%

	2023	2024
Net sales	530K 462K 428K 401K 751K 50.01M 756K 5.08M 1.97M 24.62M 1.99M 1.95M 85.47M	1.03M 902K 836K 782K 1.47M 97.66M 1.48M 9.92M 3.84M 48.07M 3.89M 3.8M 167M
Net income	-55.36M -48.27M -44.71M -41.85M -78.49M -5.22B -78.96M -530M -206M -2.57B -208M -203M -8.93B	-48.16M -42M -38.89M -36.41M -68.28M -4.54B -68.7M -461M -179M -2.24B -181M -177M -7.77B
Net Debt	21.78M 18.99M 17.59M 16.47M 30.88M 2.06B 31.07M 209M 80.88M 1.01B 81.77M 80.02M 3.51B	18.18M 15.85M 14.68M 13.74M 25.78M 1.72B 25.93M 174M 67.5M 844M 68.25M 66.78M 2.93B